Proof of concept (phase 0) study of clinical trial outcomes and biomarkers in early stage dementia with lewy bodies
Active Grant Awarded Last action
- Award ID
- R01AG100419
- Recipient
-
University Of Miami UEI F8THLJQSAF93
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $644,011
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 4% complete
- Place of performance
- Boca Raton, FL, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Aging awarded the University of Miami $644,011 on September 17, 2026, under Grant R01AG100419 in the Aging Research program (CFDA 93.866). The University of Miami's Office of Research Administration, School of Medicine division, is the recipient. The grant funds a proof-of-concept (Phase 0) study of clinical trial outcomes and biomarkers in early-stage dementia with Lewy bodies. The study characterizes the one-year rate of change in early-stage DLB and tests two digital assessments, CogniVue Clarity (CogniVue) and WCG's Virtual Reality Functional Capacity Assessment Tool (VRFCAT). It also evaluates a new Lewy Body Dementia Domain Rating Scale (LBD-DRS) and two innovative DLB biomarkers, including quantitative p-synuclein129. The work responds to the lack of DLB biomarkers and clinical trial outcome measures, since current alpha-synuclein markers are qualitative. The period of performance runs from the September 17, 2026 award date to an ultimate completion date of May 31, 2031. Place of performance is Boca Raton, Florida. The source identifies no sub-recipients for this award.
Description
- Abstract
- Approximately 1.6 million people in the united states suffer from lewy body dementia, which includes both dementia with lewy bodies (DLB) and parkinson's disease (PD) with dementia (PDD). Unfortunately, DLB diagnoses, especially early-stage DLB (which includes DLB-MCI and mild DLB) can be difficult, with patients seeing more than 3 physicians and experiencing an 18-month delay to diagnosis with misdiagnoses commonly occurring in over 60% of cases. There are no FDA-approved treatments, greatly lagging research efforts being developed in ad and PD. At the present time, DLB diagnostic, prognostic, and theragnostic biomarkers are limited and IT has been unclear as what exactly are the best clinical trial outcomes to demonstrate efficacy in a DLB trial - this has implications for the initiation and success of future DLB trials. Many commonly used dementia efficacy outcomes were developed for ad clinical trials (e.g., adas-COG, adcs-ADL), and IT is uncertain how well these measures perform in DLB or what the expected annual rate of change is. There are limitations in studying mechanisms or quantifying efficacy due to the lack of biomarkers for DLB. Most studies of DLB have used biomarkers of ad (amyloid, TAU) or PD (DOPAMINE). Current markers for alpha-synuclein are qualitative (present VS absent), making them less useful as a measure of target engagement or a clinical trial outcome. To address these great unmet needs, we propose a proof-of-concept (phase 0) study to characterize the one-year rate of change for early-stage DLB with a focus on testing the utility of two novel FDA-cleared/qualified digital assessments - COGNIVUE clarity (COGNIVUE) and WCG's virtual reality functional capacity assessment tool (VRFCAT); a new lewy body dementia domain rating scale (LBD-DRS); and two innovative DLB biomarkers - quantitative P-SYNUCLEIN129 from skin biopsies (CND life sciences) and multiplex proteomic profiles with nulisa (alamar biosciences argo). Our specific aims are: (1) recruit 60 early-stage, biopsy-confirmed DLB patients into a 12-month phase 0 study with 20 age-matched healthy controls as a comparison group using standard ad and PD clinical trial measurements; (2) test novel and innovative clinical trial outcome measures in early-stage DLB for 1-year rate of change; and (3) identify novel biomarker patterns for clinical progression over a 1-year period. The lack of research in DLB characterization and quantitative biomarker development has hindered the development of robust clinical trials to test novel therapeutics. Findings from this study will inform the design of future clinical trials in early-stage DLB by identifying tools that could be used to assess disease progression across cognitive, functional, motor and behavioral outcomes, provide effect size estimates for proper power calculations, be sensitive to measure response to therapy, confirm target engagement, and quantify changes in alpha-synuclein in trials testing disease-modifying medications.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $644,011 |
Quick answers
Who received award R01AG100419?
R01AG100419 was awarded to University Of Miami by National Institute on Aging (National Institutes of Health) on September 17, 2026.
How much is award R01AG100419 worth?
$644,011 has been obligated on R01AG100419.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award